scholarly article | Q13442814 |
P50 | author | Konrad Hoetzenecker | Q38640028 |
Burkhard Kleuser | Q59916784 | ||
Michael Trauner | Q62560551 | ||
Eva Untersmayr | Q88238661 | ||
Emina Halilbasic | Q90399354 | ||
Peter Jaksch | Q90399357 | ||
P2093 | author name string | Lili Kazemi-Shirazi | |
Lukasz Japtok | |||
Denise Heiden | |||
Elisabeth Fuerst | |||
Askin Kulu | |||
Susanne C Diesner | |||
P2860 | cites work | Export of sphingosine-1-phosphate and cancer progression | Q27009557 |
Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M | Q27667968 | ||
Cystic fibrosis transmembrane regulator regulates uptake of sphingoid base phosphates and lysophosphatidic acid: modulation of cellular activity of sphingosine 1-phosphate | Q28205285 | ||
Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases | Q28265044 | ||
Structure and function of the CFTR chloride channel | Q28295591 | ||
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects | Q28300546 | ||
Sphingosine-1-Phosphate Is a Novel Regulator of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity | Q28548390 | ||
Sphingosine-1-phosphate: an enigmatic signalling lipid | Q29620563 | ||
Immunonutrition in patients with cyctic fibrosis leads to drop of serum amyloid A and increase of oxidative stress | Q33751136 | ||
Sphingosine 1-phosphate modulates antigen capture by murine Langerhans cells via the S1P2 receptor subtype | Q34474499 | ||
Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis | Q34524946 | ||
Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis | Q34765872 | ||
Sphingolipid metabolites in inflammatory disease | Q35061720 | ||
CFTR and sphingolipids mediate hypoxic pulmonary vasoconstriction | Q35279508 | ||
Sphingosine-1-phosphate signaling and its role in disease | Q35661485 | ||
Sources, metabolism, and regulation of circulating sphingosine-1-phosphate | Q35776618 | ||
Sphingosine-1-phosphate in allergic responses, asthma and anaphylaxis | Q36151548 | ||
Transactivation of sphingosine-1-phosphate receptors by FcepsilonRI triggering is required for normal mast cell degranulation and chemotaxis | Q36399383 | ||
Low sphingosine-1-phosphate impairs lung dendritic cells in cystic fibrosis | Q36703926 | ||
The alliance of sphingosine-1-phosphate and its receptors in immunity | Q37010807 | ||
Sphingosine-1-phosphate: the Swiss army knife of sphingolipid signaling | Q37173184 | ||
Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease | Q37317783 | ||
Lipid metabolism in cystic fibrosis | Q37390419 | ||
Prevalence of dyslipidemia in adults with cystic fibrosis | Q37624200 | ||
Lipids in cystic fibrosis | Q37920895 | ||
The role of sphingolipids in respiratory disease | Q37928817 | ||
Localization of cystic fibrosis transmembrane conductance regulator to lipid rafts of epithelial cells is required for Pseudomonas aeruginosa-induced cellular activation | Q38346649 | ||
Cystic fibrosis from the gastroenterologist's perspective | Q38704228 | ||
Ceramide mediates lung fibrosis in cystic fibrosis | Q39884057 | ||
Serum Lipoprotein Concentrations in Cystic Fibrosis | Q40126324 | ||
Sphingosine-1-phosphate phosphatase 2 promotes disruption of mucosal integrity, and contributes to ulcerative colitis in mice and humans | Q41979804 | ||
Lipoprotein patterns in adult cystic fibrosis: a cause for concern or marker for survival? | Q42960756 | ||
Therapeutic efficacy and safety of amitriptyline in patients with cystic fibrosis. | Q45933447 | ||
Targeting S1P Receptors, A New Mechanism of Action for Inflammatory Bowel Disease Therapy. | Q46035910 | ||
Dietary and Endogenous Sphingolipid Metabolism in Chronic Inflammation | Q47170906 | ||
Tumor necrosis factor-α-mediated downregulation of the cystic fibrosis transmembrane conductance regulator drives pathological sphingosine-1-phosphate signaling in a mouse model of heart failure | Q48548660 | ||
Correction of lung inflammation in a F508del CFTR murine cystic fibrosis model by the sphingosine-1-phosphate lyase inhibitor LX2931. | Q48678102 | ||
Erythrocytes store and release sphingosine 1-phosphate in blood. | Q51084957 | ||
Relationship of decreased hepatic lipase activity and lipoprotein abnormalities to essential fatty acid deficiency in cystic fibrosis patients | Q69701881 | ||
Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum | Q73436742 | ||
Role of CD95 in pulmonary inflammation and infection in cystic fibrosis | Q83400699 | ||
Therapy of CF-patients with amitriptyline and placebo--a randomised, double-blind, placebo-controlled phase IIb multicenter, cohort-study | Q86568123 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 3 | |
P921 | main subject | cystic fibrosis | Q178194 |
sphingolipids | Q410395 | ||
P577 | publication date | 2020-03-14 | |
P1433 | published in | Nutrients | Q7070485 |
P1476 | title | Plasma Levels of the Bioactive Sphingolipid Metabolite S1P in Adult Cystic Fibrosis Patients: Potential Target for Immunonutrition? | |
P478 | volume | 12 |